Showing 831-840 of 936 results for "".
- Purple Day Is Coming on March 26, 2021 With Education and Advocacy to Destigmatize Epilepsyhttps://practicalneurology.com/news/purple-day-is-coming-on-march-26-2021-with-education-and-advocacy-to-destigmatize-epilepsy/2469531/Purple Day is coming soon on March 26th, 2021 epilepsy specialists, people living with epilepsy, and adv
- New Patient Resource-86 Migraine-Busts Myths About Migraine and Urges People to Take Back Controlhttps://practicalneurology.com/news/new-patient-resource-86-migraine-busts-myths-about-migraine-and-urges-people-to-take-back-control/2469431/A new website, 86 Migraine (86migraine.org), with the goal of helping individuals with migraine bust myths, cancel--or 86, as they say in the service industry, and have more control over their lives launched today. The website is produced by the Glob
- Fosgonimeton Well Tolerated With Possible Benefits for Alzheimer Disease in the Absence of Cholinergic Treatmenthttps://practicalneurology.com/news/fosgonimeton-well-tolerated-with-possible-benefits-for-alzheimer-disease-in-the-absence-of-cholinergic-treatment/2469991/In the phase 2 ACT-AD trial (NCT04491006), fosgonimeton (Athira Pharma, Bothell, WA) was well-tolerated, and no serious adverse events (AEs ) occurred. Mild-to-moderate AEs occurred in 89% (24/27) and 100% (26/26), respectively,
- First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer's Diseasehttps://practicalneurology.com/news/first-participant-dosed-in-phase-2-trial-of-phosphodiesterase-inhibitor-ar1001-for-alzheimers-disease/2468777/The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is being investigated for treatment of Alzheimer’s disease (AD). The 26-week double-blind placebo-controlled stu
- Anti-Inflammatory Drug Not Effective as Treatment for “Long COVID” Symptomshttps://practicalneurology.com/news/anti-inflammatory-drug-not-effective-as-treatment-for-long-covid-symptoms/2484498/Treatment with colchicine for 26 days was not shown to improve functional capacity, respiratory measures, inflammatory markers, or patient-reported outcomes in adults with the chronic condition ‘long COVID,’ according to study results published in JAMA Internal Medicine. In the article,
- New Resources Available at MoreThanMemoryLoss.com--Launched Today in Honor of National Caregivers Dayhttps://practicalneurology.com/news/new-resources-available-at-morethanmemorylosscom-launched-today-in-honor-of-national-caregivers-day/2469503/In honor of National Caregiver's Day, a new educational website and resource center, MoreThanMemoryLoss.com, has launched. The site is designed for caregivers of people who are living with dementia-related hallucinations and delusi
- Social Isolation Increases the Risk of Heart Attacks, Strokes, and Deathhttps://practicalneurology.com/news/social-isolation-increases-the-risk-of-heart-attacks-strokes-and-death/2469272/A German study, the Heinz Nixdorf Recall study (HNR) presented at the European Academy of Neurology (EAN) Virtual Congress found that people who are socially isolated are almost 50% more likely to die from any cause. It was also found that a lack of financial support independently increased the r
- Young Black and Latino People May Fare Better Than Whites After Hemorrhagic Strokehttps://practicalneurology.com/news/young-black-and-latino-people-may-fare-better-than-whites-after-hemorrhagic-stroke/2469136/Young black and Latino people may be less likely than young white people to be disabled or even die within 3 months of a hemorrhagic stroke. This is reported in a clinical study published in Neurology, which focused on younger people who have had hemorrhagic stroke. Of whites in the stu
- Promising Results Reported for Oral Therapy for Obstructive Sleep Apneahttps://practicalneurology.com/news/promising-results-reported-for-oral-therapy-for-obstructive-sleep-apnea/2474868/Treatment with AD109 (Apnimed, Cambridge, MA), an investigational oral therapy for obstructive sleep apnea (OSA), was found to significantly reduce the apnea-hypopnea index (AHI) at 26 weeks (P=.001), according to topline results from the phase 3 SynAIRgy clinical study (NCT05813275). AD109 treat
- Lecanemab, an Antibody to Amyloid Beta, Reduced Amyloid Levels and Cognitive Declinehttps://practicalneurology.com/news/lecanemab-an-antibody-to-amyloid-beta-reduced-amyloid-levels-and-cognitive-decline/2469653/Preliminary assessment of results clinical trials of lecanemab (BAN2401; Biogen, Cambridge, MA; Eisai, Tokyo, Japan) for potential treatment of Alzheimer disease (AD), were presented at the Alzheimer’s Association International Conference July 26-30, 2021. Lecanemab reduced brain